Skip to main contentSkip to navigation
Sirius Investors

Ascentage Pharma Group International (AAPG) Investment Research Dashboard

About Ascentage Pharma Group International (AAPG) stock analysis

Get live AAPG stock price $18.89, comprehensive Ascentage Pharma Group International stock analysis, charts, news, sentiment, sector analysis, and expert forecast. Real-time AAPG stock data and investment insights.

18.89
3.28%Today
Market Cap
1.76B
Volume
1.86K
52W High
48.45
52W Low
16.36

Loading chart data...

Investment Score

TTM (current)
Unavailable

A systematic tri-factor framework (valuation, quality, momentum) using trailing twelve-month fundamentals and current price momentum—aligned with the full investment score dashboard.

Score unavailable for this asset.

0-39

Defensive posture

40-54

Mixed / wait for confirmation

55-69

Constructive setup

70-100

Attractive zone

Total Score

Value

Cheapness vs fundamentals and cash generation

Quality

Durability of profitability and balance sheet

Momentum

Price trend strength and persistence

Professional usage: treat the score as a ranking and risk-filtering tool, then confirm with earnings revision trend, competitive positioning, and valuation relative to peers before capital allocation.

Company Overview

Based in Suzhou, China, Ascentage Pharma Group International is a biotechnology firm primarily focused on clinical-stage development. The company is dedicated to discovering and advancing therapeutic solutions for a range of medical conditions, inclu...

Company Information

CEO
Dajun Yang
Sector
Healthcare
Industry
Biotechnology
Employees
767

Contact Information

Address
Suzhou Industrial Park
Country
CN

Investment Analysis & Business Insights

Healthcare
Biotechnology

Investment Highlights

Strong presence in the Healthcare sector with established market position

Lower volatility stock (Beta: 0.66) may provide portfolio stability

Important Investment Considerations

  • All investments carry risk, including potential loss of principal for Ascentage Pharma Group International shareholders
  • Market volatility can significantly impact stock price, especially for smaller companies
  • Sector-specific risks in Healthcare may affect company performance
  • Past performance does not guarantee future results for Ascentage Pharma Group International
  • Investors should consider how Ascentage Pharma Group International fits within their overall portfolio allocation
  • Valuation metrics suggest potential, but require fundamental analysis

Market Cap

1.76B

P/E Ratio (TTM)

-11.70

Beta

0.66

Data Sources & Methodology

Financial data on this page is sourced from verified SEC EDGAR filings (10-K, 10-Q, 8-K reports), real-time market data providers, and official company disclosures. All analysis is generated using AI models trained exclusively on reliable financial documents. For detailed information about our data sources and methodology, see our Methodology page.Not investment advice.

About Healthcare Sector

The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.

Healthcare (1D)

82/100 ⭐⭐⭐⭐⭐

Overall
-0.1%
NYSE
-0.1%
NASDAQ
-0.1%
Sector1D1W1MP/EScore
Financial Services-0.1%+1.1%+1.8%19.3
84/100⭐⭐⭐⭐⭐
Healthcare-0.1%+2.4%+1.2%23.5
82/100⭐⭐⭐⭐⭐
Communication Services+0.4%-2.3%+2.0%22.2
71/100⭐⭐⭐⭐⭐
Consumer Defensive+1.3%+1.5%+0.3%29.2
69/100⭐⭐⭐⭐
Basic Materials-0.7%+0.4%-1.8%24.9
55/100⭐⭐⭐⭐
Energy-0.4%-0.6%-2.5%19.4
48/100⭐⭐⭐
Real Estate-1.6%+1.2%-2.5%29.4
48/100⭐⭐⭐
Utilities-1.5%+1.7%-2.7%25.4
48/100⭐⭐⭐
Consumer Cyclical-0.3%-2.2%-4.6%43.1
17/100
Industrials-0.4%+0.0%-8.8%30.5
17/100
Technology-1.9%-1.0%-5.5%41.9
12/100

Sector returns combine NYSE and NASDAQ averages. P/E is the latest blended sector multiple. Sector score ranks each sector vs peers using percentile ranks (not fixed thresholds): 48% 1M + 24% 1W + 8% 1D + 20% P/E (lower P/E ranks higher). Data as of 2026-07-28.